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Background: Insulin resistance (IR) is a risk factor for ischaemic heart disease and myocardial infarction (MI). IR
often manifests in MI and is regarded as an independent predictor of in-hospital mortality, which can provide
early risk stratification for recurrent acute coronary events.
Methods: The study enrolled 200 patients (130 males and 70 females aged 61.4 ± 1.12 years) diagnosed with ST
elevation MI. At days 1 and 12 from the MI onset, IR levels and lipid profiles, as well as serum glucose, insulin,
adipokine and ghrelin levels, were measured.
Results: Free fatty acid (FFA) levels had the most pronounced changes: IR patients had a 9-fold increase in FFA
levels at day 1, and patients without IR had a 6-fold increase. Leptin levels at days 1 and 12, in IR patients were,
on average, 1.5- and 2-fold higher compared to the controls and patients with no IR (р < 0.05). Leptin levels in IR
patients were increased throughout the entire hospital stay. Resistin levels in IR patients were, on average, 1.4-fold
higher throughout the entire hospital stay, while in non-IR patients, resistin levels were similar to the controls.
Adiponectin levels in IR patients were decreased compared to the controls, while in patients with IR, they were
similar to the controls. Both IR and non-IR MI patients had 3-fold and 3.7-fold lower ghrelin levels at day 1, respectively,
compared to the controls. The correlation analysis showed a negative correlation between ghrelin and FFA (r = −0.48
р = 0.007), ghrelin and leptin (r = −0.4 р = 0.003), ghrelin and insulin (r = −0.54 р = 0.002), and ghrelin and glucose
(r = −0.31 р = 0.002) in MI patients.
Conclusion: Dyslipidaemia, along with insulinaemia and glycaemia, is one of the most significant IR risk factors in the
acute and early recovery phases of MI. Dyslipidaemia is characterised by a high FFA level; an imbalance of leptin,
resistin, and adiponectin; and a deficiency of ghrelin in the acute and early recovery periods of MI. FFA and ghrelin can
be used as promising molecular markers to stratify the risk of recurrent acute coronary events and diabetes mellitus in
MI patients.
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Insulin resistance (IR) is a risk factor for ischaemic heart
disease and myocardial infarction (MI) [1]. IR often
manifests in MI and is regarded as an independent pre-
dictor of in-hospital mortality, which can provide early
risk stratification for recurrent acute coronary events
[1,2]. Currently, there is no common understanding of
pathogenetic associations between IR and complicated
MI. In terms of pathogenesis, IR is a rather heterogenic
phenomenon; therefore, a range of parameters, including* Correspondence: evg.uchasova@yandex.ru
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reproduction in any medium, provided the ortraditional hyperinsulinaemia and hyperglycaemia, are
considered to be IR markers [3]. However, some lipid
metabolism parameters are also thought to be promising
IR markers [4], with their role in cardiovascular diseases
being well established. It is known that free fatty acids
(FFAs) block glucose transport by inhibiting insulin’s
interaction with hepatocytes and monocytes, leading to
hyperglycaemia and IR development [5]. Additionally,
the current hypothesis that a range of adipose tissue and
gastric endocrine cell mediators can play an important role
in lipid metabolism regulation and IR development is being
actively discussed [6-8]. Medical literature indicates that
adipokines such as leptin, resistin and adiponectin take partral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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on the important role of ghrelin in glucose and lipid metab-
olism as well as energy homeostasis regulation suggest that
ghrelin plays a role in IR development [7]. Despite extensive
study of a wide range of IR parameters, searching for and
implementation of new approaches to IR assessment seems
to be relevant to predicting MI and its complications.
This study was aimed at determining the most inform-
ative lipid metabolism and adipokine status parameters
to assess IR in MI.
Methods
Study subjects and design
The study enrolled 200 patients (130 males and 70 females
aged 61.4 ± 1.12 years) diagnosed with ST elevation MI.
The diagnosis was verified based on clinical, electrocar-
diographic (ECG), echocardiographic (ECHO) and bio-
chemical characteristics of MI (2007 National Cardiology
Society Guidelines). The exclusion criteria were a history
of type 2 diabetes mellitus and severe concomitant
diseases affecting the prognosis, i.e., anaemia, renal or
hepatic insufficiency, cancers, worsening of infectious
or inflammatory diseases, and autoimmune conditions.
The inclusion criteria were MI within 24 hours from
the onset and no age restrictions.
All study was carried out in compliance with the Helsinki
Declaration, and its protocol was approved by the Ethical
Committee of Research Institute for Complex Issues of
Cardiovascular Diseases under the Siberian Branch of the
Russian Academy of Medical Sciences and all patients par-
ticipated the study under their written informed consent.
A structured mathematical model was used to assess
IR levels at days 1and 12 based on fasting plasma insulin
and glucose values and calculating the QUICKI index
(Quantitative Insulin Sensitivity Check Index) (Katz A.
et al. 2000) according to the following formula: QUICKI
= 1/[log (I0) + log (G0)], where I0 is baseline insulinaemia
(mMU/mL), and G0 is baseline glycaemia (mg/dL). Ac-
cording to A. Katz et al. (2000), the mean QUICKI index
of 0.382 ± 0.007 correlates with normal tissue sensitivity
to insulin, while the QUICKI indexes of 0.331 ± 0.010 and
0.304 ± 0.007 correlate with moderate and intensive IR
[3]. According to the QUICKI index, all of the patients
were divided into two groups: Group 1 included 46 pa-
tients (23%) with normal tissue sensitivity to insulin, and
group 2 included 154 patients (77%) with the QUICKI
index correlating to moderate and intensive IR. Clinical
characteristics of the patients are presented in Table 1.
The patient groups were sex- and age-matched. The
IR group had a higher incidence of such cardiovascular
risk factors as arterial hypertension, hypercholesterolaemia,
obesity and a family history of ischaemic heart disease
(IHD). Additionally, IR patients were more often diagnosed
with angina pectoris and chronic heart failure (CHF).IR in MI patients was associated with a higher inci-
dence of anterior Q-wave MI. Among their in-hospital MI
complications, IR patients often had Killip II acute heart
failure, arrhythmia and early postinfarct angina. Further-
more, 50% of patients in both the groups smoked.
MI patients received medical therapy according to the
2007 National Cardiology Society Guidelines. All of the pa-
tients received ASA, clopidogrel, beta blockers, ACE inhib-
itors and antianginal drugs, if not contraindicated; all of
the medications were administered according to the stand-
ard of care, and 100% of patients received statins (Table 2).
Primary percutaneous coronary intervention (PCI) of the
infarct-related artery was used as a reperfusion therapy
in 181 (90.5%) patients; systemic thrombolysis with strep-
tokinase (1.5 mln. ME) or pharmacological treatment were
administered to 12 (96%) and 7 (3.5%) patients, respect-
ively. The control group included 33 gender- and age-
matched subjects with no cardiovascular diseases.
Assays
Blood serum and plasma were tested. The serum was sep-
arated from venous blood by centrifugation at 3000 g for
20 min and stored at − 70°C. At days 1 and 12 from the
MI onset, levels serum glucose were measured with using
standard Thermo Fisher Scientific test systems (Thermo
Fisher Scientific Oy, Vantaa, Finland) in a Konelab 30i bio-
chemistry analyzer (Thermo Fisher Scientific Oy), insulin
and C-peptide levels were measured with BCM Diagnos-
tics lab kits (Germany). FFA, total cholesterol (TC), triac-
ylglycerols (TAG), low-density lipoproteins (LDL), very-
low-density lipoproteins (VLDL), apolipoprotein B (apo B),
high-density lipoproteins (HDL) and apolipoprotein A1
(apo A1) C-reactive protein (CRP) levels were measured at
the same study time points using standard Thermo Fisher
Scientific test systems (Thermo Fisher Scientific Oy, Vantaa,
Finland) in a Konelab 30i biochemistry analyzer (Thermo
Fisher Scientific Oy). C-peptide and insulin concentra-
tions were measured by ELISA with BioMedica (Waterloo,
NSW, Australia) and Diagnostic Systems Laboratories
(Webster, TX, USA) lab kits respectively. The intra-assay
coefficients of variation (CVs) for insulin Diagnostic Sys-
tems Laboratories and C-peptide ELISA were 3.8 and 4.2%,
respectively, and the inter-assay CVs were 6.9 and 7.9%, re-
spectively. Adipokine (leptin, adiponectin, resistin and
ghrelin) levels were measured with the BioVendor R&D
Product (Brno, Czech Republic) and intra-assay CVs were
5.9 and 6.8%. Additionally, all of the patients had their post-
prandial glycaemia, insulin and C-peptide levels measured
2 hours after eating a standard solid containing 360 kcal
(protein 20 g, carbohydrate 57 g and fat 9 g).
Statistical analysis
The statistical analysis was performed using Statistica 6.1
and SPSS 17.0 for Windows. The results were presented
Table 1 Initial clinical and anamnestic characteristics of patients, n (%)
Variable Сontrol (n = 33) Patients with MI
without IR (n = 46)
Patients with MI
and IR (n = 154)
p-value
QUICKI, n(%) 0.380 0.308 0.025
(0.378;0,384) (23%) (0.306;0.10) (77%)
Men, n(%) 18(60) 29 (63.00) 90 (58.41) 0.208
Age, (years) Clinical measures 58(51;62) 58.15 (44.00;73.50) 59.43 (48.01;72.10) 0.070
Body mass index, (kg/m2) 23.6(21.3;26.5) 25.86 (23.21;30.10) 29.97 (26.91;34.55) 0.045
Overweight, kg, n(%) Clinical measures 14 (30.41) 117 (75.91) 0.017
Arterial hypertension, n(%) 18 (39.11) 93 (60.40) 0.030
Current smoking, n(%) 2(6.6) 23 (50.01) 75 (48.70) 0.350
Family history of IHD, n(%) 5(16) 15 (32.60) 66 (42.86) 0.045
Clinic angina to myocardial infarction, n(%) 28 (60.87) 83 (53.90) 0.540
Previous myocardial infarction, n(%) 8 (17.39) 52 (33.76) 0.042
Cerebrovascular accident/transient ischemic attack in history 5 (10.87) 9 (5.84) 0.680
The depth of lesion
- Q-wave MI 34 (74.00) 130 (84.40) 0.045
- Non-Q-wave MI 12 (26.00) 24 (15.60) 0.056
Localization of MI
- Posterior 9 (19.61) 60 (38.96) 0.032
- Posterior taking the right ventricle Front 3 (6.50) 9 (5.80) 0.562
Acute heart failure (Killip) 12 (26.00) 69 (44.81) 0.035
-I 29 (63.00) 84 (54.51) 0.032
-II 9 (19.60) 44 (28.60) 0.034
-III 6 (13.00) 25 (16.30) 0.081
-IV 2 (4.40) 1 (0.60) 0.528
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(Q1;Q3). The statistical analyses were performed using the
non-parametric Mann–Whitney test and the Wilcoxon
test for skewed distributions. The exact Fisher’s test was
used to analyse the difference in the frequencies in two
independent groups with two-sided confidence intervals.Table 2 Revascularization and drug therapy during
follow-up
Therapy, n (%) All patients
n = 200
β-blockers 179 (89.5)
Angiotensin-converting enzyme 164 (82)







Thrombolysis 12.2 (6.1)Stepwise logistic regression and an ROC-curve (receiver
operating characteristic) with the area under the curve
(AUC) measurement were used to determine the most
informative IR parameters, the hazard ratio (HR) and the
confidence interval (95%).
Results
The IR group had increased glucose levels from day 1 to
day 12. The prediabetic status in MI manifested as 1.5-,
1.4- and 1.9-fold higher postprandial glucose, insulin and
C-peptide levels, respectively, compared to the controls
(Table 3). IR was diagnosed in 77% of the MI patients. The
MI patients without IR had mildly increased glucose levels
at days 1 and 12 with normal insulin and C-peptide levels
(Table 3).
The IR group had a statistically significant increase in
TC, TAG, LDL, apo-B and the apo-B/apo-A1 ratio as
well as a decrease in HDL and Apo-A compared to the
non-IR and control groups (Table 4). FFA levels had
the most pronounced changes: IR patients had a 9-fold
increase in FFA levels at day 1, and patients without IR
had a 6-fold increase; the study groups were signifi-
cantly different for this parameter (Table 4). By day 12,
Table 3 Basal and postprandial level glucose, insulin и C-peptide at 1 and 12 days of the myocardial
infarction development
Variable
Control (n = 33) Patients with MI without IR (n = 46) Patients with MI and IR (n = 154)
Basal level Postprandial
level











































Notes: acompared with control, (p < 0.05).
breliable differences in the parameters on the 1st and 12th (p < 0.05).
creliable differences between the groups on day 1 (p < 0.05).
dreliable differences between the groups on day 12 (p < 0.05).
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however, they were still more than 2-fold higher than
the controls.
At days 1 and 12, serum leptin levels in IR patients
were, on average, 1.5- and 2-fold higher compared to the
controls and patients with no IR (р < 0.05), respectively
(Table 5). Leptin levels in IR patients were increased
throughout the entire hospital stay; however, in non-IR
patients, leptin levels decreased by day 12.
Resistin levels in IR patients were, on average, 1.4-fold
higher throughout the entire hospital stay, while in non-
IR patients, resistin levels were similar to the controls.
Adiponectin levels in IR patients were decreased com-
pared to the controls, while in patients with preserved tis-
sue sensitivity to insulin, they were similar to the controls.
The study showed that ghrelin levels decreased signifi-
cantly unlike the other parameters under study. Both IR
and non-IR MI patients had 3-fold and 3.7-fold lower
ghrelin levels at day 1, respectively, compared to the
controls. The MI groups were significantly different inTable 4 Lipid profile in patients with myocardial infarction at
Variable Control,
n = 33
Patients with MI w
1-th day
TC, mmol/liter 4.30 (3.51;6.10) 4.71 (3.91;6.45)
TG, mmol/liter 1.13 (0.78;1.23) 1.15 (0.88;1.35)
HDL-C, mmol/liter 1.31 (1.02;1.72) 1.02 (0.82;1.17)
LDL-C, mmol/liter 2.03 (1.51;2.55) 2.13 (1.53;2.57)
VLDL-C, mmol/liter 0.44 (0.33;0.53) 0.52 (0.40;0.61)
apo B, g/L 1.02 (0.76;1.25) 1.00 (0.78;1.26)
apo A1, g/L 1.43 (1.29;1.73) 1.05 (0.93;1.49)a
apo-В/apo-А1 0.71 (0.59;1.01) 0.90 (0.72;1.16)
FFA, mcmol/L 0.20 (0.10;1.10) 1.20 (0.81;1.86)a
Abbreviations: TC, Total cholesterol; TG, Triglycerides; HDL-C, Cholesterol high-densit
very-low-density lipoproteins; apo B, Apolipoprotein B; apo A1, Apolipoprotein A.
Notes: areliable differences from control (p<0.05).
creliable differences in the indicators on the 1 and 12days (р<0.05);
breliable differences in the parameters between the groups (р<0.05).terms of the changes in this parameter. The correlation
analysis showed a negative correlation between ghrelin
and FFA levels (r =−0.48 р = 0.007), ghrelin and leptin levels
(r = −0.4 р = 0.003), ghrelin and insulin levels (r = −0.54
р = 0.002), and ghrelin and glucose levels (r = −0.31
р = 0.002) in MI patients.
The most informative IR markers among glucose
metabolism parameters were glucose, insulin and C-
peptide levels assessed at day 12 from the MI onset.
Higher glucose, C-peptide and insulin levels caused 2.8-
fold, 2-fold and 3.65-fold increased risks of IR, respectively.
Among lipid metabolism parameters, only FFA levels
were independently associated with IR development in
MI. An FFA increase of 1 mmol/L at day 1 was associated
with 2.9-fold increased risk of IR. However, this parameter
was not highly specific and sensitive, which was shown by
an AUC of 0.7, reflecting the average quality of the model
(Table 5). We therefore studied diagnostic sensitivity of
FFAs combined with other markers. If FFA levels were
combined with another markers, the AUC increased up to1 and 12 days of the myocardial infarction development
ithout IR, n = 46 Patients with MI and IR, n = 154
12-th day 1-th day 12-th day
4.35 (3.90;5.00) 6.00 (5.21;7.01)ac 5.80 (4.90;7.01)c
1.83 (1.37;2.28)b 1.85 (1.31;2.51)ac 2.14 (1.48;2.97)b
1.02 (0.83;1.24) 0.98 (0.74;1.30)a 0.96 (0.80;1.13)a
2.45 (1.81;3.90) 3.10 (2.49;3.63)ac 3.35 (2.64;4.26)bc
0.83 (0.62;1.04)b 0.84 (0.59;1.14)ac 0.97 (0.67;1.35)b
1.28 (1.05;1.38)b 1.26 (1.07;1.51)ac 1.42 (1.04;1.69)b
1.54 (1.19;1.75)b 1.27 (1.15;1.43)a 1.28 (1.14;1.51)
0.81 (0.69;1.09) 0.97 (0.81;1.25)a 0.94 (0.77;1.31)c
0.50 (0.43;0.69)b 1.80 (1.42;213)ac 0.57 (041;091)b
y lipoproteins; LDL-C, Cholesterol low-density lipoproteins; VLDL-C, Cholesterol
Table 5 Dynamics of adipokines and ghrelin concentrations in patients at 1 and 12 days of the myocardial
infarction development
Variable Control, n = 33 Patients with MI without IR, Patients with MI and IR,
n = 46 n = 154
1-th day 12-th day 1-th day 12-th day
Leptin, ng/ml 6.98 (4.50;9.75) 108.2 (8.01;25.91)a 9.20 (7.27;13.0)b 15.44 (8.62;30.07)a 15.62 (8.7;25.29)d
Resistin, ng/ml 7.00 (3.81;9.82) 6.64 (3.82;11.15) 6.86 (3.74;10.51) 9.94 (8.48;10.78)ac 9.19 (7.98;12.08)d
Adiponectin, mg/ml 11.35 (7.30;13.51) 11.35 (9.71;16.56) 12.20 (9.81;17.01) 9.88 (8.41;15.20)ac 9.90 (8.34;14.71)d
Ghrelin, ng/ml 55.20 (31.61;90.21) 18.36 (18.14;18.43)a 18.21 (17.89;18.73) 15.07 (13.81;17.59)ac 14.97 (13.57;17.61)d
CRP, mg/l 1,15 (0,86:2,1) 22,6 (14,0:39,0)a 6,0 (5,0:12,0)b 27,93 (11,41:51,28)a 13,0 (4,05:22,2)ab
Notes: acompared with control (p<0.05).
breliable differences in the parameters on the 1 and 12days (p<0.05).
creliable differences between the groups on day 1 (p<0.05).
dreliable differences between the groups on day 12 (p<0.05).
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model. Measuring the key inflammation marker showed
that at day 1 MI patients without IR (the whole study
population) had 19,1-fold increased CRP concentrations.
At the same time the patients with MI and IR CRP con-
centrations 24.3-fold higher (Table 5). At day 12 CRP
concentrations decreased in the both groups but were
still, 5.2-fold higher with the MI patients and 11.3 patients
with MI and IR.
Such parameters as adiponectin, leptin and resistin were
not diagnostically significant enough to detect IR in MI
patients (Table 6). The AUC showed that ghrelin was the
most sensitive and specific IR marker, especially in early
MI phases. Low ghrelin levels at day 1 from the MI onset
were associated with the risk of IR increased by 78%.
Assessing ghrelin levels in combination with FFA levels
increased the diagnostic significance of the latter in ref-
erence to IR detection. When these parameters were
combined and assessed during the early phase of MI, AUC
was 0.86, which reflected the high quality of the model.
Discussion
Studying mechanisms of IR development in different
pathologic conditions, including MI, is a relevant issue.
According to P J Stubbs et al. (1999), IR in MI patientsTable 6 The odds ratio (OR) for the development of insulin re
Variable 1-th day MI
OR 95%-й CI p-value
Glucose, mmol/liter 1.17 0.97-1.40 0.090
Insulin, mU/ml 1.10 1.04-1,17 0.002
C-peptide, ng/ml 1.08 0.72-1.62 0.710
FFA, mcmol/L 2.90 1.38-6.11 0.005
Adiponectin, mg/ml 0.94 0.88-1.01 0.110
Leptin, ng/ml 1.01 0.98-1.05 0.380
Resistin,ng/ml 0.96 0.90-1.03 0.240
Ghrelin, ng/ml 0.22 0.09-0.52 0.000can help predict adverse disease outcome within 3 years of
follow-up [10,11]. IR manifestation in the early phase of
MI is one of the typical body responses to catecholamine
stress. In this study, new IR was diagnosed in 77% of
MI patients during their hospital stay (Table 1) and was
associated with a more severe disease course: higher inci-
dences of large Q-wave MI and in-hospital complications.
In this study, IR was diagnosed using traditional markers,
i.e., serum insulin and glucose levels as well as the IR
index [3]. Basal and postprandial hyperglycaemia, high
postprandial insulin and C-peptide levels in the early
recovery phase, and decreased QUICKI index were the
markers of IR. The increase in glucose, insulin and C-
peptide levels were associated with 2.8-, 3.65- and 2-fold
higher risks of IR, respectively (Table 5). This can be
regarded as a consequence of pancreatic dysfunction and
impaired β-adrenergic glucose metabolism regulation in
hepatocytes during catecholamine stress.
IR in MI patients was associated with a cluster of car-
diovascular risk factors, including hypertension, obesity
and dyslipidaemia, characterised by higher VLDL and
TAG levels and lower HDL levels (Table 3). Moreover,
IR patients had a sharp rise in plasma FFA, which might
be a marker of excess lypolysis activation, impaired energy
homeostasis in cardiomyocytes and IR manifestation insistance in the hospital stay of myocardial infarction
12-th day MI
AUG OR 95%-й CI p-value AUG
0.58 2.80 1.66-4.73 0.000 0.79
0.76 3.65 1.79-7.41 0.000 0.98
0.58 2.10 1.02-4.33 0.040 0.64
0.70 1.82 0.60-5.51 0.290 0.56
0.61 0.97 0.91-1.02 0.230 0.63
0.57 1.06 1.01-1.11 0.020 0.66
0.66 0.91 0.85-0.99 0.120 0.70
0.87 0.57 0.42-0.76 0.000 0.82
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logistic regression analysis: among all of the lipid profile
markers, only FFA levels were closely associated with IR
in MI (Table 5). Higher FFA levels in the acute phase of
the disease were associated with a 3-fold increased IR risk.
Measuring both FFA and insulin levels in the acute phase
led to a better diagnostic value of FFAs, which is logical in
terms of pathogenesis. FFAs are able to stimulate insulin
secretion in pancreatic beta-cells, decrease insulin hepatic
clearance, and impair receptor and postreceptor insulin
signalling, which all result in postprandial hyperinsulinae-
mia and IR progression [12].
Adipokines, which are the essential regulators of energy
metabolism that modulate insulin synthesis and secretion,
play an important role in IR pathogenesis [13,14]. To
study the role of adipokine status, we chose markers
with different mechanisms of action towards insulin:
leptin and resistin are IR mediators and inductors, while
adiponectin increases tissue sensitivity to insulin [14].
Low adiponectin levels observed in diabetes, metabolic
syndrome and coronary artery disease can lead to IR [14].
The study results showed the increased adipokine levels,
which intensified IR (Table 4). High leptin and resistin
levels were accompanied by a higher IR index during the
entire hospital stay. Leptin in supraphysiological doses
in vitro is known to block insulin interaction with its
receptor on the cell membrane, which is associated with
impaired insulin-mediated glucose transport, hypergly-
caemia and more severe IR [15,16]. Additionally, according
to Opie et. al. (2008), high leptin levels intensify FFA oxida-
tion and lead to diacylglyceride build-up, which, in turn,
induces IR [17]. Another adipokine, resistin, is an an-
tagonist of insulin [18]. Resistin inhibits insulin-mediated
glucose uptake by the target tissues and decreases FFA
consumption and their metabolism in the skeletal muscles
through the activation of AMP-activated protein kinase
[19]. Generally, the increase in the above-mentioned
adipokine levels can have a negative effect on insulin
production, secretion and cell signalling, which may
induce IR in MI.
Unlike leptin and resistin, the protective effects of adi-
ponectin decreased during the hospital stay, especially
in IR patients. Adiponectin is known to neutralise the
lipotoxic effect of FFA, inducing endothelial dysfunc-
tion and IR [20]. The decrease in adiponectin levels is
likely to promote FFA lipotoxic effect, which certainly
contributes to IR development and progression. This
assumption is supported by the results of a correlation
analysis showing a negative correlation between FFA
and adiponectin levels.
The role of ghrelin, a gastrointestinal endocrine peptide
and an important regulator of growth factor secretion,
desire for food and energy homeostasis, in IR patho-
genesis has been actively discussed recently [7,21,22]. Itwas found that cardiomyocytes are able to produce
ghrelin, which has diverse protective effects, including
the inhibition of cardiomyocyte and endothelial cell
apoptosis and improved left ventricular function in ischae-
mia/reperfusion [23].
Ghrelin is known to modulate insulin secretion and,
therefore, is regarded as a promising molecular IR marker.
Ghrelin was shown to contribute to the expression of
α- and β-insulin receptor subunits. At the same time,
1–10 nm/L of insulin inhibit basal and noradrenaline-
stimulated ghrelin secretion but do not influence ghrelin
mRNA expression [24]. Obese children have lower ghrelin
levels that those with normal metabolism; at the same
time, ghrelin had a strong positive correlation with the
HOMA-IR index irrespective of anthropometric and
metabolic parameters of IR syndrome [25]. Additionally,
in diabetic patients, metformin therapy, which improves
tissue sensitivity to insulin, was accompanied by higher
ghrelin levels [26-28]. In this study, ghrelin levels were
significantly decreased in MI patients during the entire
hospital stay; in patients with IR, the changes were more
pronounced. Previously, it was shown that MI patients
have decreased ghrelin levels, which, in the authors’
opinion, is due to an enhanced binding of ghrelin with its
receptor in ischaemia/reperfusion [29]. We suggest that in
MI, the inhibition of ghrelin secretion may also be due to
the imbalance in the adipokine system accompanied by
the dysfunction of insulin-secreting pancreatic cells,
impaired lipid metabolism and IR manifestation. Our
assumption is supported by the results of experimental
studies that demonstrate the antagonistic relationship
between leptin and ghrelin [30,31] and the ability of high
FFA levels to block ghrelin secretion [7] as well as by
the result of a correlation analysis showing the nega-
tive correlation between leptin and ghrelin and be-
tween insulin and FFA in MI patients. Additionally,
the ghrelin level appears to be a more informative IR
marker than traditional markers and adipokine status
parameters in both the acute and recovery MI phases
(Table 5). Ghrelin, as a marker of IR in MI, has high
diagnostic sensitivity and specificity (82-87%). Ghrelin
has a better diagnostic value than insulin in the acute
MI phase, and assessing both ghrelin and FFA levels
increased the diagnostic significance of the latter with
regard to IR.
Conclusion
Thus, insulin resistance was observed in 77% of MI patients
and was associated with a history of cardiovascular risk
factors, an adverse disease course and impaired lipid
metabolism. Among lipid metabolism parameters, FFAs
are of the greatest interest in terms of IR detection in
MI patients. The 9-fold higher FFA levels in the acute
MI phase are associated with a 3-fold higher risk of
Gruzdeva et al. BMC Cardiovascular Disorders 2014, 14:7 Page 7 of 7
http://www.biomedcentral.com/1471-2261/14/7impaired tissue sensitivity to insulin. The diagnostic
value of FFA assessment is higher when insulin and
ghrelin levels are also measured. Adipokine imbalance
in MI manifesting in higher leptin and resistin levels,
which impair tissue sensitivity to insulin and inhibit
protective adiponectin effects, is accompanied by IR
development. Ghrelin levels are the most informative
marker in terms of IR detection in the acute phase of MI;
it has high specificity and sensitivity. A 4-fold decrease in
ghrelin levels is associated with a 78%-higher risk of IR.
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